Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials ; volume:24 ; number:1 ; day:18 ; month:12 ; year:2024 ; pages:1-11 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (18.12.2024), 1-11, 12.2024

Creator: Wang, Zhenzi
Liu, Yuan
Wang, Kedi
Ma, Liyan

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12876-024-03554-8

URN: urn:nbn:de:101:1-2503010622305.282204551503

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wang, Zhenzi
Liu, Yuan
Wang, Kedi
Ma, Liyan
SpringerLink (Online service)

Other Objects (12)

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Comparing VIP and PD‐L1 expression as cancer biomarkers

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Regulatory mechanisms of PD-1/PD-L1 in cancers

PD-1/PD-L1 binding studies using microscale thermophoresis

The PD-1:PD-L1 axis in Inflammatory Arthritis

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Related objects

Reset password